Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A French Nationwide Study of Ninety‐Two Patients
暂无分享,去创建一个
X. Mariette | L. Mouthon | F. Maurier | T. Martin | E. Lazaro | B. Crestani | I. Machelart | X. Puéchal | R. Dhôte | P. Hatron | B. Godeau | F. Cohen-Aubart | L. Guillevin | G. Hayem | B. Terrier | P. Cohen | C. Blanchard-Delaunay | J. Cadranel | J. Kahn | C. Le Jeunne | C. de Moreuil | E. Crickx | F. Vandergheynst | G. Le Guenno | Y. Ollivier | N. Silva | A. Mania | A. Mehdaoui | N. M. Silva
[1] D. Metze,et al. Nomenclature of cutaneous vasculitides – German translation of the dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[2] A. Fioravanti,et al. Granulomatosis with polyangiitis and intravenous immunoglobulins: a case series and review of the literature. , 2015, Autoimmunity reviews.
[3] A. Khasnis,et al. Venous thromboembolism in systemic autoimmune diseases: A narrative review with emphasis on primary systemic vasculitides , 2015, Vascular medicine.
[4] P. Ravaud,et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. , 2014, The New England journal of medicine.
[5] O. Decaux,et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. , 2014, Rheumatology.
[6] P. Merkel,et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. , 2013, The New England journal of medicine.
[7] E. Gelfand. Intravenous immune globulin in autoimmune and inflammatory diseases. , 2012, The New England journal of medicine.
[8] M. Cheng,et al. Special Considerations with the Use of Intravenous Immunoglobulin in Older Persons , 2011, Drugs & aging.
[9] S. Kaveri,et al. Intravenous immunoglobulin therapy in rheumatic diseases , 2011, Nature Reviews Rheumatology.
[10] M. Ballow. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. , 2011, The Journal of allergy and clinical immunology.
[11] D A Bloch,et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. , 2010, Arthritis and rheumatism.
[12] L. Hobson‐Webb,et al. Case-control study of thromboembolic events associated with IV immunoglobulin , 2009, Journal of Neurology.
[13] David Steven Scott,et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.
[14] S. Kaveri,et al. Modulation of the cellular immune system by intravenous immunoglobulin. , 2008, Trends in immunology.
[15] R. Seror,et al. High frequency of venous thromboembolic events in Churg–Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients , 2008, Annals of the rheumatic diseases.
[16] H. Gürcan,et al. Frequency of Adverse Events Associated with Intravenous Immunoglobulin Therapy in Patients with Pemphigus or Pemphigoid , 2007, The Annals of pharmacotherapy.
[17] D. Abramowicz,et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. , 2007, Journal of the American Society of Nephrology : JASN.
[18] A. Achiron,et al. Safety of intravenous immunoglobulin (IVIG) therapy. , 2007, Autoimmunity reviews.
[19] H. Raspe,et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis , 2006, Annals of the rheumatic diseases.
[20] L. Cavacini,et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. , 2006, The New England journal of medicine.
[21] I. Marie,et al. Intravenous immunoglobulin‐associated arterial and venous thrombosis; report of a series and review of the literature , 2006, The British journal of dermatology.
[22] D. Scott,et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies , 2006, Annals of the rheumatic diseases.
[23] D. Hamrock,et al. Adverse events associated with intravenous immunoglobulin therapy. , 2006, International immunopharmacology.
[24] T. Kita,et al. Clinical Efficacy of Intravenous Immunoglobulin for Patients with MPO-ANCA-Associated Rapidly Progressive Glomerulonephritis , 2005, Nephron Clinical Practice.
[25] G. Danieli,et al. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome , 2004, Annals of the rheumatic diseases.
[26] F. Bonilla. PROSPECTIVE AUDIT OF ADVERSE REACTIONS OCCURRING IN 459 PRIMARY ANTIBODY-DEFICIENT PATIENTS RECEIVING INTRAVENOUS IMMUNOGLOBULIN , 2004, Pediatrics.
[27] H. Chapel,et al. Prospective audit of adverse reactions occurring in 459 primary antibody‐deficient patients receiving intravenous immunoglobulin , 2003, Clinical and experimental immunology.
[28] D. Adu,et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. , 2000, QJM : monthly journal of the Association of Physicians.
[29] C. Gordon,et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.
[30] D. Jayne,et al. Intravenous immunoglobulin as sole therapy for systemic vasculitis. , 1996, British journal of rheumatology.
[31] W. Gross,et al. Treatment of anti‐neutrophil cytoplasmic antibody (ANCA)‐associated systemic vasculitis with high‐dose intravenous immunoglobulin , 1995, Clinical and experimental immunology.
[32] D. Adu,et al. Anti‐idiotypic activity against anti‐myeloperoxidase antibodies in pooled human immunoglobulin , 1994, Clinical and experimental immunology.
[33] D. Jayne,et al. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. , 1993, Journal of autoimmunity.
[34] M. Davies,et al. Treatment of systemic vasculitis with pooled intravenous immunoglobulin , 1991, The Lancet.
[35] M. Kazatchkine,et al. Anti‐idiotypes against anti‐neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis , 1991, Clinical and experimental immunology.
[36] Katsuko Sato,et al. HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.
[37] A. Hirt,et al. HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD , 1981, The Lancet.
[38] P. Merkel,et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.
[39] L. Mouthon,et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. , 2011, Clinical and experimental rheumatology.
[40] R. Panush. Rituximab versus cyclophosphamide for ANCA-associated vasculitis , 2011 .
[41] K. Bassett,et al. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. , 2009, The Cochrane database of systematic reviews.
[42] L. Mouthon,et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. , 2008, Arthritis and rheumatism.
[43] A. Gibofsky. American College of Rheumatology. , 2002, Journal of the Medical Association of Georgia.
[44] O. Lortholary,et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. , 1996, Medicine.
[45] D. Jayne,et al. Pooled intravenous immunoglobulin in the management of systemic vasculitis. , 1993, Advances in experimental medicine and biology.